- Active not recruitingPHASE1
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
This study is testing a new medicine called Andexanet. It's for healthy people aged 18 to 55. We want to see how Andexanet works with common blood thinners like Rivaroxaban and Apixaban, and if it affects another blood thinner called Enoxaparin. This helps doctors understand how to use Andexanet safely.
For: Healthy ParticipantsGermany · United Kingdom - RecruitingPHASE3
Thromboprophylaxis in Lower Limb Immobilisation
This study looks at new ways to prevent blood clots after a leg injury treated with a cast or splint. It compares injections with tablets and also checks if medication helps those at lower risk of clots. The goal is to find safer and more effective options.
For: Thrombosis · Injury LegUnited Kingdom - Active not recruiting
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study looks back at patient records to understand how different blood-thinning medicines work for people with cancer who have also had blood clots. It compares medicines like Apixaban, Rivaroxaban, and Dabigatran to see which are most effective and safe.
For: Neoplasms · EmbolismUnited Kingdom - RecruitingPHASE4
THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
This study looks at whether blood-thinning medicines can help prevent blood clots after common varicose vein operations. It aims to see if giving these medicines after keyhole procedures for varicose veins is a good idea to keep you safe.
For: Venous Thromboembolism · Varicose VeinsUnited Kingdom - Ongoing, recruitingPhase III and phase IV (Integrated)
SHORT RUN AF. Rivaroxaban versus standard of care for patients with excessive atrial ectopy or short atrial runs and high embolism risk
This study is testing a blood-thinning medicine called rivaroxaban. It's for people with irregular heartbeats (short atrial runs) who are at high risk of stroke. We want to see if rivaroxaban can prevent strokes while being safe.
France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Study of Andexanet Alfa Compared to Usual Care in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery or Procedure (ANNEXA-RS)
This study is comparing a new medication called Andexanet Alfa to usual care. It's for patients who are taking blood thinners (like apixaban, rivaroxaban, or edoxaban) and need urgent surgery. The aim is to see if Andexanet Alfa helps stop bleeding during their operation.
For: Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban · rivaroxaban · or edoxaban) who require urgent surgery or procedureFrance · Portugal · Spain - Ongoing, recruitingTherapeutic use (Phase IV)
Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease (GENPAD)
This study looks at how well different blood-thinning medicines work for people with narrowed leg arteries (PAD). It compares standard care with a new approach using genetic tests to help choose the best medicine to prevent serious problems like heart attacks, strokes, or limb issues.
For: Peripheral Arterial DiseaseNetherlands - Active not recruiting
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study looks back at French health records to understand how different blood-thinning medicines affect people with an irregular heartbeat (atrial fibrillation) who are at higher risk of stomach bleeding. It compares older medicines like warfarin with newer ones to see how safe and effective they are.
For: Atrial FibrillationUnited Kingdom